Latest Pharma and Biotech News
Biotechnology
26 November 2024 US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement.
Today's issue
Refine Search
Pharmaceutical
Swiss drugmaker Idorsia was trading more than 10% higher by lunchtime on Wednesday. Idorsia earlier announced that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan. 27 November 2024
Biosimilars
Samsung Bioepis has appointed Kyung-Ah Kim as its new president and chief executive, succeeding Christopher Hansung Ko, who will lead the Samsung Future Business Division. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Pharmaceutical
Japanese drugmaker Otsuka has announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for the manufacture and sale in Japan of bempedoic acid - trade name Nexletol in Japan - for the treatment of hypercholesterolemia and familial hypercholesterolemia. 27 November 2024
Pharmaceutical
Berlin, Germany-based Eckert & Ziegler Radiopharma has received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand, by the European Commission (EC). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
All news
Pharmaceutical
The androgen receptor blocker Xtandi (enzalutamide) has performed well in a Phase III trial testing its use in a new indication. 17 March 2023
Pharmaceutical
Following announcements in in the last few days, first by Eli Lilly and then by Novo Nordisk, French pharma major Sanofi revealed that it too would slash the US price of its insulin products. 17 March 2023
Pharmaceutical
Esperion Therapeutics’ shares plunged by over 60% to $1.64 on Thursday, after it stated in a company filing with Securities and Exchange Commission (SEC) that Daiichi Sankyo Europe has disputed Esperion’s right to receive milestone payments following a clinical trial. 17 March 2023
Pharmaceutical
Implementation is moving forward on President Joe Biden’s Inflation Reduction Act (IRA) policy that allows Medicare to negotiate lower prescription drug prices. 16 March 2023
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) is recommending the use of Zolgensma (onasemnogene abeparvovec) as an option in babies with presymptomatic 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and up to three copies of the SMN2 gene, said Swiss Pharma giant Novartis. 16 March 2023
Biotechnology
Japanese drugmakers Ono Pharmaceutical and PeptiDream have entered into a new drug discovery collaboration to discover and develop novel macrocyclic constrained peptide drugs against multiple targets of Ono’s interest. 16 March 2023
Biotechnology
Fibrosis-focused Mediar Therapeutics has added $105 million to its coffers. 16 March 2023
Biotechnology
The planned merger of Jounce Therapeutics and UK-based Redx Pharma came under threat yesterday, when Jounce confirmed that it has received an unsolicited offer from Concentra Biosciences to acquire 100% of the company. 16 March 2023
Biotechnology
BioSenic, a Belgian firm specializing in severe inflammatory diseases and cellular repair, has announced that it has re-evaluated the results of its Phase III trial of the enhanced viscosupplement JTA-004 targeting knee osteoarthritis (OA). 16 March 2023
Pharmaceutical
Dermavant Sciences, an immuno-dermatology-focused subsidiary of Switzerland-based Roivant Sciences, has disclosed highly compelling Phase III data from the ADORING 2 trial, the first top-line data from Vtama (tapinarof) in atopic dermatitis (AD) of a two-trial series. 16 March 2023
Pharmaceutical
In a highly unusual move, the UK pharmaceutical industry’s trade body has suspended the membership of Danish diabetes giant Novo Nordisk. 16 March 2023
Biotechnology
During the 2023 JP Morgan Healthcare Conference, the most important venue of the sector, three M&A deals were announced, raising expectations for a return of industry consolidation and much-needed support for biotech companies. 16 March 2023
Biotechnology
Belgian drugmaker UCB has teamed up with US firm Aitia in an early drug discovery collaboration focused on the discovery and validation of new drug targets and candidates for Huntington’s disease. 15 March 2023
Pharmaceutical
The impact of US President Joe Biden's Inflation Reduction Act is beginning to be felt, as Danish diabetes giant Novo Nordisk announced plans to slash the cost of insulin. 15 March 2023
Biotechnology
The US Department of Health and Human Services (HHS), through the Centers for Medicare and Medicaid Services (CMS), has announced 27 prescription drugs for which Part B beneficiary coinsurances may be lower from April 1 to June 30. 15 March 2023
Biotechnology
One year after their original agreement, Dutch antibody-drug conjugate (ADC) specialist Synaffix has expanded a deal with MacroGenics. 15 March 2023
Pharmaceutical
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has unleashed a broadside against decision-makers in Brussels. 15 March 2023
Biotechnology
British biopharmaceutical companies have welcomed an announcement from the UK’s Chancellor, Jeremy Hunt, of a new enhanced R&D tax relief rate for certain innovators. 15 March 2023
article
Shares of Texas, USA-based Bellicum Pharmaceuticals tanked almost 50% to $0.46 this morning after it said it has decided to discontinue its ongoing Phase I/II clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. 15 March 2023
Biotechnology
Servier, a French pharma major governed by a non-profit foundation, today revealed that the Phase III INDIGO clinical trial investigating vorasidenib in monotherapy for patients with residual or recurrent IDH mutant low-grade glioma met its primary endpoint of progression free survival (PFS) and the key secondary endpoint of time to next intervention (TTNI). 15 March 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze